Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with our proprietary computational discovery platform to identify new drug targets and biological pathways that could enhance anti-cancer immune responses. With these new targets in hand and a deep understanding of their underlying biology, we are advancing new therapeutics and optimizing their combination to expand immuno-oncology treatment options to cancer patients who are not responsive to currently available drugs.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.